There are unique concerns about the developability properties of antibody-drug conjugates (ADCs) due to the conjugation process.
With multi-parameter assessment of CQAs, it is possible to examine multiple aspects of ADC stability in parallel, to ensure the final product has the greatest chance at clinical success, while saving time and sample early in development.
In this webinar, Product Manager Rebecca Hood dives into the practical considerations of ADC development and characterization.
- What formulation considerations are critical during ADC development
- How to use high-resolution stability data to compare your ADCs to unconjugated antibodies
- Which characteristics are impacted by the conjugation process, and how they influence your selection and development process
Check out further video resources from this webinar: